Emerging Superpowers of Clinical Research - Russia, India, China

28-29 May 2009, Amsterdam, Netherlands.
Faster patient recruitment and potential for cost savings are only a few of the factors attracting international sponsors to the emerging regions of clinical research. Countries like the Russian Federation, India and China offer similar attractions, as well as raising similar questions, when being considered as a location for clinical trials.

Similarities between these three countries include large patient pools enabling rapid recruitment due to massive treatment-naïve populations with diseases of both the developed and developing world. Russia, India and China are the next pace setters for pharmaceutical clinical trials, bringing both opportunities and challenges for the industry. The increasing inclusion of these markets in international trials indicates that leading Pharma and Biotech are recognising the advantages of conducting trials in these regions.

Aside from large patient populations, key benefits of these countries include: low cost of services, highly-competent labor pools and well equipped sites. However, local practices which differ from country to country, such as cultural, language, logistical, ethical and local regulatory requirements can make life challenging for companies performing clinical research. Specific issues faced by clinical trial operations across these three markets include protection of patients’ rights and safety, regulatory compliance, inconsistent data quality, lack of sufficient numbers of trained clinical researchers and even site saturation.

This event will examine in detail the opportunities in these unique markets which present the fastest global growth in clinical trials for timely, high-quality and cost-effective clinical development. Experienced speakers will help you understand the differing cultural and other aspects which are essential for successful conduct of clinical trials, including establishing of strong business relationships and ensuring trials’ compliance with ICH GCP Guidelines.

NextLevel Pharma's "Emerging SUPERPOWERS in Clinical Research" event will also provide dedicated, 1 on 1 partnering sessions enabling sponsor companies (Pharma, Biotech, Vaccine, Diagnostic and Medical device manufacturers) to meet with CROs, Central Labs, leading consultants, software and other clinical solution providers experienced in these growing markets to discuss potential partnerships.

For further information and registration, please visit:
https://www.nextlevelpharma.com/events/view/emerging_superpowers_of_clinical_research

About NextLevel Pharma
NextLevel Pharma is a leading, global strategic business information and opportunity provider for the international life sciences industry.

NextLevel Pharma brings the life sciences industry closer together and organise intelligent conferences and events for industry, personalised meetings for individual companies, as well as tailored partnering services.

For more information, please visit www.nextlevelpharma.com.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...